RXBIO, INC.

 

  Follow

Location: USA

Founded in 2010

Privately Held


Develops proprietary compounds for mitigating acute radiation syndrome, focusing on gastrointestinal and hematological radiation syndrome, with lead compound Rx100 aiming to prevent radiation-induced death.
"RxBio, Inc. is an early-stage pharmaceutical company. RxBio was formed around novel and proprietary, small-molecule technology developed at the University of Tennessee Health Science Center (UTHSC) in Memphis and licensed from the University of Tennessee Research Foundation (UTRF). The company's primary focus is the discovery and development of novel and proprietary compounds for use in the mitigation of acute radiation syndrome (ARS) – including gastrointestinal acute radiation syndrome (GI-ARS) as well as hematological radiation syndrome (HEM-ARS). Rx100 has shown significant efficacy for GI-ARS in both large and small animal models with survival as the endpoint. RxBio’s lead molecule, Rx100 is a metabolically stable analog of lysophosphatidic acid (LPA). Our preliminary data showed that Rx100 significantly inhibited toxin-induced and mediated secretory diarrhea. Rx100 could prove to..."
Description Source: VentureRadar Research / Company Website

Updates


US Small Business Administration (SBA) Award
Grant
22 Dec 2020
Amount: $252,128.00 | Targeted Therapies for the Treatment of GI-ARS Diarrhea
US Small Business Administration (SBA) Award
Grant
31 Dec 2015
Amount: $222,829.00 | The anti-diarrheal potential of a LPA analog Rx100
US Small Business Administration (SBA) Award
Grant
31 Dec 2015
Amount: $297,087.00 | Development of Rx100 as Novel Medical Countermeasure for Acute Radiation Syndrome
US Small Business Administration (SBA) Award
Grant
31 Dec 2011
Amount: $194,797.00 | TAS::75 0849::TAS
US Small Business Administration (SBA) Award
Grant
31 Dec 2008
Amount: $99,977.00 | Development of an LPA receptor modulator Rx100 as a radioprotectant
US Small Business Administration (SBA) Award
Grant
31 Dec 2007
Amount: $97,162.00 | LPA Receptor Modulators as Radioprotectants
View Funding Rounds for Keywords: Biotechnology; Biotech
Export Similar Companies

Similar Companies


Company Country Status Description
Dansk BiotekUnknownn/a
DANISH BIOTECH is a trade organization for Danish biotech companies with the aim to promote opportunities for biotechnology research, development and production in Denmark and...
Doma BioChinan/a
Doma is an innovative biotechnology company with an independent drug research and development pipeline that also functions as a biotech incubator with flexible and diverse...
SwissGenesis GmbHSwitzerlandPrivately Held
An innovative Swiss Biotech company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, anti-aging,...
Innoland BiosciencesUnknownn/a
Innoland Biosciences is a multi-platform biotechnology company engaged in innovative R&D and advanced technological services. Innoland’s mission is to effectively accelerate the...
CinnagenIrann/a
CinnaGen Co. was founded in 1994 with the goal of manufacturing hi-tech products in biotechnology and related fields. Since its start of operation with 4 scientists, CinnaGen has...
Nona BiosciencesUSAn/a
Nona Biosciences is a leading global biotechnology company dedicated to cutting edge technology innovations. We provide a total solution for partners worldwide, from academic...
Show all

Related Top Ranked Companies Lists


BiotechnologyBiotech
VentureRadar Score

Is this your company?

Claim this profile and
update details for free
Sub-Scores
Social Proof
750
Website Traffic
n/a
Auto Analyst Score
620
Popularity on VentureRadar
883
Auto Analyst Score
62
Auto Analyst Score: 62 | RXBIO.COM
VentureRadar Popularity
Medium
VentureRadar Popularity: Medium
The popularity score combines profile views, clicks and the number of times the company appears in search results.

Free Sign-up for VentureRadar access

or






By continuing, you agree to VentureRadar's Terms of Service, Privacy Policy and Cookie Policy.

To continue, please confirm you are not a robot